JCR Pharmaceuticals Co

Summary

Organization: JCR Pharmaceuticals Co
Country: Japan

Top Publications

  1. ncbi The cleavage site specificity of human prostate specific antigen for insulin-like growth factor binding protein-3
    E Okabe
    Development and Research Laboratories, JCR Pharmaceuticals, Kobe, Japan
    FEBS Lett 447:87-90. 1999
  2. doi Efficient production of active Vibrio proteolyticus aminopeptidase in Escherichia coli by co-expression with engineered vibriolysin
    Hiroyuki Sonoda
    Research Center, Research Division, JCR Pharmaceuticals Co, Ltd, Kobe 651 2241, Japan
    Appl Microbiol Biotechnol 84:191-8. 2009
  3. ncbi Improved solubilization of recombinant human growth hormone inclusion body produced in Escherichia coli
    Hiroyuki Sonoda
    Medical Technology Research Center, Research Division, JCR Pharmaceuticals Co, Ltd, Kobe, Japan
    Biosci Biotechnol Biochem 72:2675-80. 2008
  4. doi Extracellular production of active vibriolysin engineered by random mutagenesis in Escherichia coli
    Hiroyuki Sonoda
    Research Division, Medical Technology Research Center, JCR Pharmaceuticals Co, Ltd, Kobe, Japan
    Protein Expr Purif 62:153-9. 2008
  5. ncbi Characterization of group a streptococcal M23 protein and comparison of the M3 and M23 protein's ligand-binding domains
    Kyongsu Hong
    Laboratories for Bioengineering and Research, JCR Pharmaceuticals Co, Ltd, 2 2 10 Murotani, Nishi ku, Kobe 651 2241, Japan
    Curr Microbiol 55:427-34. 2007
  6. ncbi Characterization of the arginine deiminase of Streptococcus equi subsp. zooepidemicus
    Kyongsu Hong
    Laboratories for Bioengineering and Research, JCR Pharmaceuticals Co, Ltd, Kobe, Japan
    Can J Microbiol 52:868-76. 2006
  7. ncbi Identification and characterization of a novel fibronectin-binding protein gene from Streptococcus equi subspecies zooepidemicus strain VTU211
    Kyongsu Hong
    Laboratories for Bioengineering and Research, JCR Pharmaceuticals Co, Ltd, 2 2 10 Murotani, Nishi ku, Kobe 651 2241, Japan
    FEMS Immunol Med Microbiol 45:231-7. 2005
  8. ncbi Protein C inhibitor as an anti-disseminated intravascular coagulation agent--mechanism and modification
    M Fujita
    Pharmacological Science, Research Center, Research and Development Division, JCR Pharmaceuticals Co Ltd, 2 2 10 Murotani, Nishi ku, Kobe 651 2241, Japan
    Curr Med Chem Cardiovasc Hematol Agents 2:21-7. 2004
  9. ncbi Development of a high-throughput bioassay to screen melatonin receptor agonists using human melatonin receptor expressing CHO cells
    Tetsuo Yokoyama
    JCR Pharmaceuticals Co, Ltd, Pharmaceutical Science, Research Center, Research and Development Division, 2 2 10 Murotani, Nishi ku, Kobe 651 2241, Japan
    Neurosci Lett 344:45-8. 2003
  10. ncbi Role of each Asn-linked glycan in the anticoagulant activity of human protein C inhibitor
    Mitsugu Fujita
    Development and Research Laboratories, JCR Pharmaceuticals Co, Ltd, 2 2 10 Murotani, Nishi ku, Kobe 651 2241, Japan
    Thromb Res 105:95-102. 2002

Scientific Experts

Detail Information

Publications16

  1. ncbi The cleavage site specificity of human prostate specific antigen for insulin-like growth factor binding protein-3
    E Okabe
    Development and Research Laboratories, JCR Pharmaceuticals, Kobe, Japan
    FEBS Lett 447:87-90. 1999
    ..In contrast, our purified urinary prostate specific antigen had only a chymotrypsin-like activity, demonstrating that prostate specific antigen has the high substrate specificity for human insulin-like growth factor binding protein-3...
  2. doi Efficient production of active Vibrio proteolyticus aminopeptidase in Escherichia coli by co-expression with engineered vibriolysin
    Hiroyuki Sonoda
    Research Center, Research Division, JCR Pharmaceuticals Co, Ltd, Kobe 651 2241, Japan
    Appl Microbiol Biotechnol 84:191-8. 2009
    ..This purified aminopeptidase effectively converted methionyl-human growth hormone (Met-hGH) to hGH. Thus, this co-expression system provides an efficient method for producing active recombinant V. proteolyticus aminopeptidase...
  3. ncbi Improved solubilization of recombinant human growth hormone inclusion body produced in Escherichia coli
    Hiroyuki Sonoda
    Medical Technology Research Center, Research Division, JCR Pharmaceuticals Co, Ltd, Kobe, Japan
    Biosci Biotechnol Biochem 72:2675-80. 2008
    ..The biological activity of the resulting r-hGH was comparable with commercially available r-hGH in in vitro cell proliferation assay using the hGH-dependent cell line...
  4. doi Extracellular production of active vibriolysin engineered by random mutagenesis in Escherichia coli
    Hiroyuki Sonoda
    Research Division, Medical Technology Research Center, JCR Pharmaceuticals Co, Ltd, Kobe, Japan
    Protein Expr Purif 62:153-9. 2008
    ..2mg/L of purified protein. This suggests that the novel engineered vibriolysin is useful for overproduction in an E. coli expression system...
  5. ncbi Characterization of group a streptococcal M23 protein and comparison of the M3 and M23 protein's ligand-binding domains
    Kyongsu Hong
    Laboratories for Bioengineering and Research, JCR Pharmaceuticals Co, Ltd, 2 2 10 Murotani, Nishi ku, Kobe 651 2241, Japan
    Curr Microbiol 55:427-34. 2007
    ....
  6. ncbi Characterization of the arginine deiminase of Streptococcus equi subsp. zooepidemicus
    Kyongsu Hong
    Laboratories for Bioengineering and Research, JCR Pharmaceuticals Co, Ltd, Kobe, Japan
    Can J Microbiol 52:868-76. 2006
    ..The recombinant protein also possessed AD activity. By immunoblot analysis using both anti-SzSAGP-SfbI(H8) and anti-SfbI(H8) sera, I was able to demonstrate that the SzSAGP protein is expressed on the streptococcal surface...
  7. ncbi Identification and characterization of a novel fibronectin-binding protein gene from Streptococcus equi subspecies zooepidemicus strain VTU211
    Kyongsu Hong
    Laboratories for Bioengineering and Research, JCR Pharmaceuticals Co, Ltd, 2 2 10 Murotani, Nishi ku, Kobe 651 2241, Japan
    FEMS Immunol Med Microbiol 45:231-7. 2005
    ..Purified FNZ2(2-4) protein was also shown to display collagen-binding activity to collagen-coated microtiter wells. These results show that recombinant FNZ2 has fibronectin- and collagen-binding activities...
  8. ncbi Protein C inhibitor as an anti-disseminated intravascular coagulation agent--mechanism and modification
    M Fujita
    Pharmacological Science, Research Center, Research and Development Division, JCR Pharmaceuticals Co Ltd, 2 2 10 Murotani, Nishi ku, Kobe 651 2241, Japan
    Curr Med Chem Cardiovasc Hematol Agents 2:21-7. 2004
    ..This review introduces the anti-DIC action of PCI and about the modification of N-glycosylation site(s) of PCI to heighten the value of PCI as an anti-DIC agent...
  9. ncbi Development of a high-throughput bioassay to screen melatonin receptor agonists using human melatonin receptor expressing CHO cells
    Tetsuo Yokoyama
    JCR Pharmaceuticals Co, Ltd, Pharmaceutical Science, Research Center, Research and Development Division, 2 2 10 Murotani, Nishi ku, Kobe 651 2241, Japan
    Neurosci Lett 344:45-8. 2003
    ..Therefore, this FLIPR assay, using melatonin receptor and Gqi5 expressing CHO cells, is available for clinical bioassay of melatonin and for the screening of specific ligands of melatonin...
  10. ncbi Role of each Asn-linked glycan in the anticoagulant activity of human protein C inhibitor
    Mitsugu Fujita
    Development and Research Laboratories, JCR Pharmaceuticals Co, Ltd, 2 2 10 Murotani, Nishi ku, Kobe 651 2241, Japan
    Thromb Res 105:95-102. 2002
    ..These results suggest that the Asn243-linked glycan in PCI molecule possesses critical roles for its anticoagulant activity in the circulation, and the Asn230-linked glycan down-regulates the activity of PCI...
  11. ncbi The trimannosyl cores of N-glycans are important for the procoagulant protease-inhibitory activity of urinary protein C inhibitor
    W Izutani
    Development and Research Laboratories, JCR Pharmaceuticals Co, Ltd, 2 2 10 Murotani, Nishi ku, Kobe 651 2241, Japan
    Thromb Res 104:65-74. 2001
    ..These results suggest that the trimannosyl cores of N-glycans are important for uPCI to inhibit the procoagulant protease...
  12. ncbi Amino-terminal fragment of urokinase-type plasminogen activator inhibits HIV-1 replication
    M Wada
    Laboratories for Bioengineering and Research, JCR Pharmaceuticals Company, Ltd, 2 2 10 Murotani, Nishi ku, Kobe, 651 2241, Japan
    Biochem Biophys Res Commun 284:346-51. 2001
    ..These findings suggest that ATF may inhibit the assembly and budding of HIV-1, which provides a novel therapeutic strategy for AIDS...
  13. ncbi Production of a recombinant hybrid molecule of cholera toxin-B-subunit and proteolipid-protein-peptide for the treatment of experimental encephalomyelitis
    Y Yuki
    JCR Pharmaceuticals Co, 2 2 10 Murotani, Nishi ku, Kobe 651 2241 Japan
    Biotechnol Bioeng 74:62-9. 2001
    ..These results suggest that nasal treatment with the recombinant B. brevis-derived hybrid protein of CTB and autoantigen peptide could prove useful in the control of multiple sclerosis...
  14. ncbi Effect of urinary protein C inhibitor on lipopolysaccharide-induced disseminated intravascular coagulation in rats
    M Fujita
    Development and Research Laboratories, JCR Pharmaceuticals Co, Ltd, Kobe, Japan
    Thromb Haemost 84:54-8. 2000
    ..These results show that uPCI may prevent hypercoagulation, the induction of secondary fibrinolysis and organ failure in the DIC model. Therefore, uPCI may be a useful agent for the clinical treatment of DIC...
  15. ncbi Characterization of group A streptococcal strains Sv and Su: determination of emm gene typing and presence of small vir regulon
    K Hong
    Laboratories for Bioengineering and Research, ICR Pharmaceuticals Co, Ltd, Kobe, Japan
    Res Microbiol 151:29-36. 2000
    ..Taken together, the data suggest that M protein could be expressed on the surface of the Sv bacteria, but not on the Su bacteria...
  16. ncbi Isolation of a fission yeast mutant cell affected in MAP kinase signaling and sterol biosynthesis
    Kiwamu Imagawa
    Division of Molecular Pharmacology and Pharmacogenomics, Department of Biochemistry and Molecular Biology, Kobe University Graduate School of Medicine, Kobe, Japan
    Kobe J Med Sci 55:E30-5. 2009
    ....